Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07226544 | Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer | recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06076538 | PET/MR for Characterization of Renal Masses (RMs) | recruiting | — | 97 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743749 | An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 307 | Xencor, Inc.INDUSTRY | 5 | Aug 3, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 30 | Neomorph, IncINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07611825 | Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma(REMEDY-RCC) | recruiting | Phase 2 | 33 | Jinling Hospital, ChinaOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05759923 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | recruiting | Phase 1 | 40 | Molecure S.A.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | recruiting | Phase 1 / Phase 2 | 55 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07646847 | A Study of a Side Effects and Resource Navigation Program for People With Cancer | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations(BEACON) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | recruiting | Phase 1 / Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07179770 | Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) | recruiting | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04113486 | Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations(ENRC) | recruiting | — | 400 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05665361 | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | recruiting | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05756569 | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | recruiting | Phase 2 | 25 | Emory UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07564232 | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | recruiting | Phase 2 | 111 | Fox Chase Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07043608 | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases(ZAMBONI) | recruiting | Phase 2 | 20 | Kelly Fitzgerald, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07062549 | Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell | recruiting | Phase 1 | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | recruiting | Phase 2 | 21 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07128680 | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03374267 | Registry Platform Urologic Cancer(CARAT) | recruiting | — | 2,230 | iOMEDICO AGINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07028125 | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma(CANIQOL) | recruiting | Phase 4 | 83 | Centre Francois BaclesseOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07092566 | R.E.C.K vs Exparel in Robotic Nephrectomy | recruiting | Phase 3 | 170 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07630155 | Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma | recruiting | N/A | 10 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03972657 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | recruiting | Phase 1 / Phase 2 | 345 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05127824 | Autologous Dendritic Cell Vaccine in Kidney Cancer | recruiting | Phase 2 | 42 | Jodi MaranchieOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07087158 | A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | recruiting | — | 800 | Henan Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07647744 | To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer | recruiting | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06101290 | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)(LAYOVER) | recruiting | N/A | 150 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672860 | Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors(PURIFY) | recruiting | Phase 2 | 146 | Jinling Hospital, ChinaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03293563 | UroCCR Database: French Research Network for Kidney Cancer -UroCCR(UroCCR) | recruiting | — | 30,000 | University Hospital, BordeauxOTHER | 4 | Jun 25, 2026 | clinicaltrials |
| NCT07321197 | Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)(RECLND) | recruiting | N/A | 220 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07321210 | Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)(UTLUND) | recruiting | N/A | 150 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07657325 | Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma | recruiting | — | 110 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07038733 | Investigation of Lymph Node Biology in Kidney Cancer(LN-RCC) | recruiting | N/A | 33 | Yale UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials